Australian Clinical Labs Limited (ASX:ACL)
Australia
· Delayed Price · Currency is AUD 2.980
+0.010 (0.34%)
Mar 31, 2025, 4:11 PM AEST
Australian Clinical Labs Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2017 |
| Net Income | 30.67 | 23.93 | 35.9 | 178.24 | 60.37 | 41.26 | Upgrade
|
| Depreciation & Amortization | 132.55 | 128.43 | 122.76 | 106.1 | 88.05 | 77.9 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.04 | 1.04 | -0.14 | 0.67 | -0.03 | -0.05 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | - | - | 0.06 | Upgrade
|
| Stock-Based Compensation | 3.06 | 3.06 | 1.88 | 1.46 | 2.17 | 0.32 | Upgrade
|
| Other Operating Activities | -0.65 | 2.64 | -10.48 | 8.14 | -9.71 | -6.22 | Upgrade
|
| Change in Accounts Receivable | -7.72 | -7.72 | 17.4 | -28.12 | 2.75 | -16.8 | Upgrade
|
| Change in Inventory | -1.73 | -1.73 | 5 | -3.9 | -2.26 | -0.83 | Upgrade
|
| Change in Accounts Payable | 11.65 | 11.65 | -17.73 | 16.49 | 5.18 | 5.75 | Upgrade
|
| Change in Other Net Operating Assets | -1.71 | -1.71 | -10.91 | 5.01 | 7.34 | 0.34 | Upgrade
|
| Operating Cash Flow | 167.16 | 159.59 | 143.68 | 284.09 | 153.86 | 101.74 | Upgrade
|
| Operating Cash Flow Growth | 8.58% | 11.07% | -49.42% | 84.64% | 51.24% | 9048.92% | Upgrade
|
| Capital Expenditures | -6.68 | -6.51 | -6.93 | -21.25 | -9.51 | -9.38 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.13 | 0.33 | 0.24 | 0.27 | 0.11 | 0.11 | Upgrade
|
| Cash Acquisitions | -0.54 | -1.07 | -5.48 | -51.06 | 2.25 | -0.69 | Upgrade
|
| Investment in Securities | - | - | - | - | 1.07 | - | Upgrade
|
| Investing Cash Flow | -0.11 | -7.25 | -12.18 | -72.04 | -6.08 | -9.96 | Upgrade
|
| Long-Term Debt Issued | - | 14 | 100.5 | - | 321.6 | - | Upgrade
|
| Total Debt Issued | 26 | 14 | 100.5 | - | 321.6 | - | Upgrade
|
| Long-Term Debt Repaid | - | -138.06 | -140.61 | -191.69 | -357.22 | -60.92 | Upgrade
|
| Total Debt Repaid | -167.09 | -138.06 | -140.61 | -191.69 | -357.22 | -60.92 | Upgrade
|
| Net Debt Issued (Repaid) | -141.09 | -124.06 | -40.11 | -191.69 | -35.62 | -60.92 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 146.25 | - | Upgrade
|
| Repurchase of Common Stock | -6.15 | -1.74 | -0.89 | -4.94 | - | - | Upgrade
|
| Common Dividends Paid | -23.86 | -19.95 | -96.88 | -24.22 | -42 | - | Upgrade
|
| Other Financing Activities | -0.21 | -0.39 | - | -0.06 | -216 | - | Upgrade
|
| Financing Cash Flow | -171.31 | -146.14 | -137.88 | -220.91 | -147.37 | -60.92 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.14 | -0.03 | -0.04 | 0.01 | -0.03 | -0.14 | Upgrade
|
| Net Cash Flow | -4.13 | 6.18 | -6.42 | -8.86 | 0.38 | 30.72 | Upgrade
|
| Free Cash Flow | 160.47 | 153.09 | 136.75 | 262.84 | 144.36 | 92.36 | Upgrade
|
| Free Cash Flow Growth | 9.30% | 11.95% | -47.97% | 82.07% | 56.31% | - | Upgrade
|
| Free Cash Flow Margin | 22.04% | 21.98% | 19.62% | 26.40% | 22.32% | 18.83% | Upgrade
|
| Free Cash Flow Per Share | 0.80 | 0.77 | 0.68 | 1.30 | 0.95 | 0.64 | Upgrade
|
| Cash Interest Paid | 18.06 | 16.67 | 13.85 | 11.39 | 39.39 | 12.49 | Upgrade
|
| Cash Income Tax Paid | 16 | 10.16 | 17.91 | 68.87 | 18.56 | -0.14 | Upgrade
|
| Levered Free Cash Flow | 167.42 | 158.2 | 126.48 | 250.39 | 170.88 | 58.52 | Upgrade
|
| Unlevered Free Cash Flow | 178.94 | 168.85 | 134.9 | 257.74 | 180.34 | 68.87 | Upgrade
|
| Change in Net Working Capital | -8.48 | -4.77 | 23.56 | -0.2 | -19.63 | 11.51 | Upgrade
|
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.